GYKI-52895

GYKI-52895
Systematic (IUPAC) name
	4-{13-methyl-4,6-dioxa-11,12-diazatricyclo[7.5.0.03,7]tetradeca-1,3(7),8,10-tetraen-10-yl}aniline
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	869360-93-0
ATC code	?
PubChem	CID 3539
ChemSpider	3418
KEGG	C15094
Synonyms	4-(8,9-Dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)benzenamine
Chemical data
Formula	C17H17N3O2
Mol. mass	295.34
	SMILES O1c2c(OC1)cc3c(c2)C(=N/NC(C3)C)\c4ccc(N)cc4;
	InChI InChI=1S/C17H17N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8,10,19H,6,9,18H2,1H3 ; Key:AQTITSBNGSVQNZ-UHFFFAOYSA-N ;
(what is this?) (verify);

GYKI-52895 is a drug which is a 2,3-benzodiazepine derivative. Unlike other similar drugs, GYKI-52895 is a selective dopamine reuptake inhibitor,^[1]^[2] which presumably would produce stimulant effects in vivo.^{[original research?]}

[edit] See also

^ Horváth K, Szabó H, Pátfalusi M, Berzsenyi P, Andrási F. Pharmacological Effects of GYKI 52895, a New Selective Dopamine Uptake Inhibitor. European Journal of Pharmacology. 1990; 183(4):1416-1417.
^ Huang CL, Chen HC, Huang NK, Yang DM, Kao LS, Chen JC, Lai HL, Chern Y. Modulation of Dopamine Transporter Activity by Nicotinic Acetylcholine Receptors and Membrane Depolarization in Rat Pheochromocytoma PC12 Cells. Journal of Neurochemistry. 1999; 72(6): 2437–2444.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.